Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
For patients with lymphoma that recurs after chemotherapy, bone marrow transplantation using
 cells from a healthy donor represents potentially curative treatment. In these individuals,
 cure is possible because transplantation of healthy donor immune cells can fight the lymphoma
 in the patient. The goal of this work is to test a strategy that activates the healthy donor
 immune cells so that they more effectively fight lymphoma and can result in an increased cure
 rate for these patients. Our group has previously studied CpG, an immune activating
 medication, in patients with lymphoma and demonstrated modest anti-tumor responses. We now
 have a more potent form of CpG which we intend to test to see if it will better activate the
 donor immune cells and result in shrinkage of tumor throughout the entire body, not just at
 the injected site.
Patients will receive low dose radiation to all bulky or symptomatic lymph nodes on days -2
 and -1. SD-101 will be administered intratumorally to the single largest palpable node within
 24 hours after completion of radiation, on day 0. Two additional intratumoral SD-101
 injections will be performed on days 7 (+/- 2 days) and 14 (+/- 2 days). This is a dose
 ranging study using a 3+3 design with a definition of maximum tolerated dose (MTD) which our
 group has found acceptable in the past. The first cohort of patients will receive a SD-101
 dose of 0.3 mg per injection. The dose will be escalated to 1 mg and 3 mg based on dose
 limiting toxicity (DLT).
Inclusion Criteria:

 -  Biopsy-confirmed relapsed, refractory, or progressive NHL or HL (Refer to Section
 3.2.1 for excluded subtypes)

 -  At least 3 sites of disease

 1. One for diagnosis (lymph node or bone marrow biopsy)

 2. One palpable for treatment

 3. One measurable radiographically

 -  > 60 days after RIC allogeneic transplant for lymphoma

 -  18 years of age or older

 -  Mixed (5-95%) or complete (>95%) chimerism

 -  Eastern Oncology Cooperative Group (ECOG) performance status ≤ 2

 -  ANC >1000/mm3, platelets >50,000/mm3

 -  Total bilirubin ≤ 2.5 mg/dL, AST and ALT < 3 times upper limit of normal

 -  Serum creatinine ≤ 3 mg/dL

 -  No chemotherapy, RT, DLI or biologic therapy for lymphoma at least 4 weeks prior to
 scheduled treatment

 -  Minimal immunosuppression (defined as monotherapy with ≤ 10 mg prednisone daily, ≤ 200
 mg cyclosporine daily, or ≤ 2 mg tacrolimus daily) at least 2 weeks prior to scheduled
 treatment

 Exclusion Criteria:

 -  HIV associated lymphoma

 -  Acute GVHD at time of enrollment (history of treated and resolved GVHD is permitted)

 -  Active infection within 14 days prior to scheduled treatment

 -  Active Cytomegalovirus (CMV) disease at the time of enrollment

 -  Pre-existing autoimmune or antibody mediated disease (including systemic lupus
 erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, and
 autoimmune thrombocytopenia)

 -  Pregnant